Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th


  • Text size: A A A
  • Circadin
  • Recent news

    • Neurim Pharmaceuticals attends the ESCAP Congress in Vienna, Austria, 30 June – 2 July 2019
    • Slenyto (PedPRM) is now also available in Italy!
    • Neurim Pharmaceuticals attends the EPA Congress in Warsaw, Poland, April 7-9, 2019
  • Partners

    Partners